Takeda Reports FY2017 Full Year Results and Issues FY2018 Guidance

OSAKA, Japan–(BUSINESS WIRE)–May 14, 2018–Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth +5.5% led by Takeda’s Growth Drivers Underlying Revenue grew +5.5%, with Takeda’s Growth Drivers (Gastroenterology, Oncology …
( read original story …)


Related Post

Japan Display affiliate becomes nation’s fir...
views 184
TOKYO (Reuters) - An affiliate of Japan Display In...
‘Tokyo Ghoul’ Season 3 Updates: Fate o...
views 258
However, with no news on whether there will bee a ...
Japan's regional bank consolidation gains mom...
views 242
TOKYO -- The planned consolidation of three region...
Japanese reporter dies after working 159 hours ove...
views 156
A JAPANESE journalist died from overwork after clo...
Japan, U.S. likely to hold economic dialogue Oct. ...
views 158
Japanese Deputy Prime Minister Taro Aso is expecte...
Nikkei hit by weak U.S. shares, strong yen; mining...
views 228
TOKYO, May 31 Japanese stocks dropped on Wednesday...
Everything you need to know about the Japanese eco...
views 232
Trading Economics | 3. The World Bank, World Integ...
Moxy Hotels Invites Osaka to Play on With Signing ...
views 76
Marriott International today announced the signing...
Vietnam Morning News For November 24
views 174
is planning a $300-million IPO this year with a ta...
Japan urges caution on any North Korea agreement
views 59
Japan's defence minister has urged the internation...